Company / Gross Profit per Share
ADMA Biologics, Inc. Gross Profit per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit per Share
$1.24
FY2025
5-year range
$0.01 / $1.24
FY2021-FY2025
Trend
+27.4%
vs FY2024
Sector context
#25 of 29
Health Care
What the data says
ADMA Biologics, Inc.'s gross profit per share of $1.24 is lower than 86% of companies in the Health Care sector (FY2025). Gross Profit per Share has increased for 3 consecutive years, from $0.01 in FY2022 to $1.24 in FY2025.
Based on SEC 10-K filings.
1.24 in FY2025 with a 3-year CAGR of +491.1%.
Improved from $0.40 to $1.24 over the past 2 years.
Health Care sector context is included.
Gross Profit per Share over time
Growth rates
- 3-Year CAGR
- +491.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 29This company $1.24 Sector average $8.11
▼
-84.7% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s gross profit per share has grown for 3 consecutive years.
- In FY2025, gross profit per share increased 27.4% year-over-year.
- Ranks #25 out of 29 companies in the Health Care sector.
- Lowest gross profit per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross Profit per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.24 | +27.4% |
| FY2024 | $0.97 | +142.2% |
| FY2023 | $0.40 | +6591.9% |
| FY2022 | $0.01 | -46.4% |
| FY2021 | $0.01 | +103.5% |
| FY2020 | -$0.32 | - |
| FY2019 | - | - |
| FY2018 | -$0.69 | -305.7% |
| FY2017 | $0.33 | -16.9% |
| FY2016 | $0.40 | +71.6% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026